This article is more than 5 years old. Information may no longer be current.
NewYork-Presbyterian, Columbia University appoint director of cellular immunotherapy
Click Here to Manage Email Alerts
Pawel Muranski, MD, has been joined NewYork-Presbyterian and Columbia University Medical Center as director of cellular immunotherapy at the newly established Good Manufacturing Practices cell production lab and assistant director of transfusion medicine and cellular therapy.
Muranski also will serve on Columbia’s faculty as assistant professor of medicine, pathology and cell biology; principal investigator at Columbia Center for Translational Immunology; and member of Herbert Irving Comprehensive Cancer Center at Columbia.
“We’re thrilled to have Dr. Muranski joining us to continue his innovative work,” Gary Schwartz, MD, chief of the division of hematology/oncology at NewYork-Presbyterian/Columbia University Medical Center, said in a press release. “His approach to T cell-based therapy holds so much potential and could revolutionize care for cancer patients, transplant patients and others.”
Muranski, a hematologist who most recently served in NHLBI’s hematology branch, specializes in bone marrow transplantation and in developing adoptive T-cell therapies.
His research focuses on exploiting and enhancing the capability of engineered T cells to recognize and target cancerous cells or dangerous viruses.
“Despite recent spectacular advances in the field of cancer immunotherapy, very few institutions have Good Manufacturing Practices laboratories with the capacity to grow and manipulate T cells,” Muranski said in the release. “NewYork-Presbyterian and Columbia University Medical Center are now positioned to become leaders in cutting-edge cellular immunotherapies. I’m excited to work with the team here on developing a comprehensive program that brings these innovative treatments to our patients.”